Organic Active Ingredients TRIZ Cases

Sequential administration of a chimeric poliovirus and lymphodepleting chemotherapy overcomes insufficient efficacy in brain tumor treatment.

Substituted indole compounds inhibit Mcl-1 activity to overcome chemotherapy resistance in cancer cells characterized by overexpression.

Merging mu-opioid agonism with sigma-1 antagonism in a single molecule mitigates tolerance and side effects while maintaining reliable pain relief.

Alginate particle encapsulation protects nicotine from oxidation and degradation while enabling rapid absorption via the oral cavity.

Pyrrolyl-sulfonamide compounds act as negative modulators of the GPR17 receptor to treat neurological disorders.

Merges combretastatin agents with CTLA-4, PD-1, or PD-L2 antibodies to prevent rapid tumor regrowth after vascular shutdown.

Small molecule chaperones enhance endogenous enzyme function to reduce adverse side effects associated with expensive enzyme replacement therapies.

Polyvalent emoxypine derivatives disaggregate alpha-synuclein aggregates, addressing disease progression limitations of current Parkinson's treatments.

Specific intravenous infusion schedules and dosages for aurora kinase inhibitors increase anti-tumor efficacy while managing side effects.

Composite preservative stabilizes nucleic acids in blood samples, resolving the contradiction between anticoagulation function and nucleic acid integrity.

Cyclodextrin-complexed estrogen maintains permissive hypotension and enhances immune responses to reduce mortality from severe trauma hemorrhage.

A two-chamber infusion preparation maintains a specific pH level through buffered amino acids and organic acids in the first chamber.

Pyrazine compounds inhibit ATR protein kinase to disrupt DNA repair, reducing off-target toxicity while maintaining potent anticancer activity.

Compounds with specific structures selectively inhibit PI3K isoforms, reducing non-specific effects on other enzymes.

Combining dextromethorphan with CYP2D6 and CYP3A4 enzyme inhibitors extends therapeutic duration.

Deuterium substitution at specific pyrimidine ring positions improves pharmacokinetic profiles and therapeutic effectiveness of ALK kinase inhibitors.

Genetic biomarker analysis identifies host susceptibility to disseminated staphylococcal infection in osteomyelitis patients.

Phenylethylamine salts with inorganic acids improve bioavailability, resolving slow onset and short duration issues.

A transdermal therapeutic system delivers tizanidine using a free base formulation within a polar and nonpolar polymer matrix.

Heterocyclic compounds activate soluble guanylate cyclase to boost cGMP levels, overcoming nitrate-induced tolerance in cardiovascular therapy.

Indazole ligands activate alpha-7 nicotinic acetylcholine receptors to treat memory impairment while reducing toxicity associated with nicotine.

Oxygen permeable polyolefin packaging minimizes glucose degradation in acidic citrate concentrates while maintaining a non-corrosive pH above 2.

Modulating SLC46A3 expression enhances tumor accumulation of lipid-based nanoparticles, overcoming low uptake rates in heterogeneous cancer lineages.

Tryptophan, tyrosine, and arginine in whey protein boost neurotransmitter concentrations to suppress appetite without prescription drug side effects.

Selective kappa opioid receptor modulators produce rapid antidepressant effects, bypassing the weeks-long delay of traditional serotonin reuptake inhibitors.

PRMT5 inhibitors suppress tumor growth by over 50 percent while minimizing body weight loss to under 4 percent.

Saponin nano micelles replace toxic synthetic polymers to increase drug loading capacity while reducing adverse reactions in pharmaceutical formulations.

Radiolabeled cotinine enables non-invasive PET imaging of amyloid-beta accumulation, replacing invasive post-mortem diagnosis with accurate in vivo monitoring.

Hydrothermal transformation of microorganisms creates a vaccine carrier retaining morphological characteristics and surface ligands.

Human serum albumin disperses cannabidiol in a liposome to slow release rates and maintain therapeutic levels for days without rapid clearance.

Plant viral capsids bypass cellular efflux pumps by transporting compounds directly into the nucleus, overcoming multi-drug resistance.

An erodible barrier layer comprising wax and multiple L-HPC grades enables steady delayed release independent of GI tract motility conditions.

Switching zoledronic acid to a disodium salt overcomes low diacid bioavailability, enabling effective pain relief with lower doses.

Metadherin inhibitors block metastasis and chemoresistance, resolving poor prognosis prediction gaps.

Di-aliphatic substituted PEGylated lipids protect siRNA from nuclease digestion while enabling efficient intracellular delivery.

Amorphous pseudopolymorphs of Compound A resolve the trade-off between stability and dissolution rate, enabling effective HCV treatment via spray drying.

Targeting OLMALINC with oligonucleotides inhibits gene expression, reducing lipogenesis and treating NAFLD while managing off-target effects.

N-(3,4-dichlorophenyl)-N-methylpropanamide targets transient receptor potential channels to reduce bone erosion without severe side effects.

Ponesimod slows brain volume loss by at least 20% relative to standard care, addressing insufficient efficacy and poor tolerance of current therapies.

One-pot condensation of indanolamine with quinolone epoxide yields stable Indacaterol maleate salt, eliminating dimer impurities and boosting yield above 70%.

Replacing expensive hydrogenation catalysts, chiral dibenzoyl tartaric acid resolves thienyl alanine isomers through selective crystallization.

Modified agelastatin A derivatives reduce tumor growth and toxicity by blocking osteopontin activity.

A glucose gel formulation uses acid addition and thermal sterilization to achieve sterility without antimicrobial preservatives.

Vibegron selectively activates beta-3 receptors to boost cardiac output while minimizing the systolic blood pressure spikes seen with less specific agonists.

SUMO1 overexpression enhances SERCA2a stability and activity, reversing contractile dysfunction in heart failure.

A pharmaceutical composition combines N-acetyl cysteine, alpha-lipoic acid, and bromelain to reduce inflammation.

Segmentation converts solid tablets into pediatric-friendly powders, while parameter changes stabilize the solvate to improve bioavailability.

A 1.6 to 3.2 mg once daily rovatirelin regimen treats ataxia while minimizing harmful thyroid hormone elevation.

Novel oxopiperazine derivatives inhibit the p300/CBP transcriptional regulator to target tumor growth.

Ligand-conjugated oligonucleotides improve cellular entry and binding specificity without requiring external delivery vehicles.

Substituted pyrimidine compounds block voltage-gated sodium channels to reduce side effects from opiate resistance.

BCAT1 inhibitors restore alpha-ketoglutarate levels in IDHwtTETwt acute myeloid leukemia, improving treatment efficacy.

Formula I heterocycles modulate skeletal muscle contractility by binding fast skeletal troponin C to improve function while reducing off-target safety risks.

Spray-drying hyaluronic acid hydrolysate yields high bulk density solids, resolving low-density issues from freeze-drying that hinder tableting adequacy.

Plant-derived pentosan polysulfate replaces animal heparin to eliminate ethical concerns while maintaining moisturizing efficacy.

Intermittent weekly administration of PKC activators prevents receptor downregulation, maintaining elevated BDNF and PSD-95 markers.

Oligoguluronates reduce mucosal viscosity while preserving gel transportability to treat constipation and lung issues in cystic fibrosis.

Covalent attachment of water-soluble oligomers to tricyclic compounds modifies pharmacokinetic profiles.

Reacting [2-(acylaminoethyl)thio]arenes with an aldehyde and acid forms 2,3,4,5-tetrahydrobenzo[1,4]thiazepines in high yield.

Segmented polyurea-polyorganosiloxane compounds use donor-acceptor interactions to boost substantivity, overcoming pH-sensitive charge limitations.

Wet milling creates stable nano-sized cocrystals with dicarboxylic acids, eliminating organic solvents and polymer costs.

Core-shell granules stabilize the active ingredient against acidic degradation while extending its half-life through controlled release.

A branched alpha-glucan promotes hydrogen gas production to regulate intestinal functions.

Nucleophilic substitution eliminates Suzuki coupling side reactions, improving ERK inhibitor yield and purity.

Targeted BRAFV600E expression in tissue macrophages resolves modeling inaccuracies and enables effective inhibitor testing.

Matrix tablet with water-insoluble polymers stabilizes opioid plasma levels, reducing peak-trough fluctuations and adverse side effects.

Polyvinyl alcohol prevents particle aggregation and size changes during freeze-drying, maintaining stability for intravenous drug delivery.

Erdafitinib targets FGFR mutations in high-risk non-muscle invasive bladder cancer, preventing disease recurrence after BCG therapy failure.

Spring-loaded plunger actuation maintains bioequivalent plasma concentration by replacing manual syringe variability with consistent mechanical force.

Switching zoledronic acid to disodium salt overcomes low oral bioavailability while maintaining manufacturing stability.

A non-pulsatile betahistine oral solid composition utilizes a hydrophilic matrix system to control drug dissolution and diffusion kinetics.

Intravenous high-dose L-triiodothyronine administration reduces microvascular obstruction following primary percutaneous coronary intervention.

Phosphodiesterase inhibitors resolve hand-foot syndrome pain and blisters, allowing patients to maintain full-dose cancer therapy without dose reductions.

Combining a TLR2 antagonist with azacitidine targets refractory myelodysplastic syndrome patients who fail hypomethylating agent therapy.

A two-layer lacosamide tablet combines immediate and extended release mechanisms.

Early-life synbiotic supplementation programs metabolic resilience against Western-style diet risks, reducing chronic inflammation and insulin resistance.

Aluminum isopropoxide reduction selectively yields trans-asenapine, eliminating chromatographic separation.

Cleavable liver-targeted ligands bind hepatocyte receptors to deliver nucleic acid molecules, resolving low cytoplasmic penetration caused by negative charges.

Chitosan-wrapped hydroxyapatite shells on zinc phosphate cores enable controlled oxaliplatin release to reduce healthy tissue toxicity.

Converting the free base into hydrochloride or fumarate salts improves bioavailability and stability while reducing side effects from receptor tolerance.

Low molecular weight dextran sulfate modifies T-lymphocyte surface properties to reduce pulmonary trapping during intravenous injection.

Integrates anti-CD30 antibody drug conjugate, anti-PD-1 inhibitor, and chemotherapy to treat refractory Hodgkin lymphoma while reducing pulmonary toxicity.

Artemisinin compounds increase beta cell number and insulin concentration, addressing limited donor islet availability.

PSA-PCL micelles replace PEG coatings to extend circulation time while avoiding immunogenicity and drug release interference.

A bis-propenamide scaffold combines cinnamaldehyde and curcumin features to induce apoptosis in cancer cells.

A phase transfer catalyzed reaction yields amorphous saroglitazar magnesium with high purity.

A therapeutic vaccine composition raises antibodies against modified Aβ peptide antigens to inhibit amyloid fibril aggregation.

Formula I compounds inhibit TLR7 and TLR8 activity, resolving the precision versus effectiveness trade-off in treating autoimmune diseases.

Benzimidazole compounds target PI3Kβ to treat PTEN-deficient cancers lacking effective therapies.

Developing crystal forms A and B of compound IV resolves stability issues in SSAO inhibitors, enabling effective treatment of non-alcoholic steatohepatitis.

Exosomes encapsulate biological agents to cross the blood-brain barrier, reducing nanotoxicity and immune clearance while extending circulation time.

Deuterium substitution at the aniline ring slows metabolic demethylation, extending half-life and reducing hepatotoxicity in EGFR mutant cancer treatment.

Specific molecular structures inhibit P2X3 and P2X2/3 receptors, addressing inadequate selectivity in current pain treatments.

Specific oxadiazole substituents optimize binding affinity and selectivity, resolving the efficacy and specificity trade-off in FLAP inhibition.

Computational modeling designs stable supramolecular therapeutics to minimize systemic toxicity while targeting tumors.